While emerging conventional wisdom may state biopharmaceutical companies could see a boon as a result of the COVID-19 pandemic thanks to new treatment and vaccine opportunities, the sector may not come out on top.

Biopharmaceutical company AstraZeneca has received more than $1 billion in funding from BARDA for the development, production and delivery of Oxford University's vaccine for COVID-19.

Testing all residents and staff at the nation’s nursing homes just once would collectively cost $440 million, according to data from the American Health Care Association and National Center of Assisted Living (AHCA/NCAL).

CMS has issued a plan to reopen the nation’s nursing homes with a new guidance for state and local officials.

CVS Health has stated it will return $43 million in funding it received for COVID-19 relief.

Hospitals and healthcare providers are facing higher costs to care for complex COVID-19 patients while also suffering the loss of other procedures like elective surgeries that could help offset these higher costs.

Civica Rx has teamed up with the U.S. government to aid in the COVID-19 response.

President Trump recently stated he was taking hydroxychloroquine, an anti-malaria drug that has been unproven to prevent or treat infection of COVID-19. Trump has touted the drug over the past several weeks for benefitting COVID-19 patients, but studies have shown little to no impact.

Americans are delaying critical stroke care as a result of the ongoing COVID-19 pandemic by not dialing 9-1-1 when they are experiencing a stroke.

The number of record breaches containing sensitive information is on the rise across multiple business sectors, including healthcare, according to a new report from Atlas VPN.

The most commonly missed condition seems to be spinal abscess, an infection that can cause paraplegia yet was fumbled in more than 62% of cases.

As analyzed by the Kaiser Family Foundation, the outlook for job-based insurance under some post-COVID scenarios is unsurprisingly bleak.